A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Pfizer
Columbia University
Washington University School of Medicine
pharmaand GmbH
Massachusetts General Hospital
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Massachusetts General Hospital
Dana-Farber Cancer Institute
GlaxoSmithKline
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Sarcoma Alliance for Research through Collaboration
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute